Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Onkos Surgical Wins FDA Nod for Eleos Proximal Tibia

What are you searching for?

Sign in
OEM News

Onkos Surgical Wins FDA Nod for Eleos Proximal Tibia with Antibacterial Tech

NanoCept technology provides a proactive approach against intraoperative bacterial contamination.

Author Image

By: Sam Brusco

Associate Editor

Eleos proximal tibia with NanoCept antibacterial technology. Photo: Onkos Surgical.

Onkos Surgical has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Eleos proximal tibia with NanoCept antibacterial technology.

NanoCept technology provides a proactive approach against intraoperative bacterial contamination. In preclinical studies supporting Eleos’ original de novo market authorization, NanoCept showed up to a 5-log reduction (99.999%) kill rate of bacteria commonly found in the operating room environment.

Eleos proximal tibia with NanoCept is part of Onkos’ Eleos limb salvage system, which provides comprehensive reconstruction options for patients with significant bone loss due to cancer, trauma, or previous surgical procedures.

Steven Gitelis, MD, director of musculoskeletal oncology at Rush University Medical Center and chief medical officer of Onkos Surgical said NanoCept is an important addition to comprehensive bacterial mitigation efforts in orthopedic surgery.

“The clearance of the ELEOS Proximal Tibia with NanoCept Antibacterial Technology allows us to extend this technology to one of the most challenging anatomical sites for bone tumors and complex bone loss,” Dr. Gitelis told the press.

“This first post-De Novo 510(k) clearance marks a major milestone, highlighting our commitment and capability to advance NanoCept technology throughout the ELEOS implant system—and ultimately beyond,” said Patrick Treacy, co-founder and CEO of Onkos. “We remain dedicated to supporting the surgeons we serve and the patients they treat by delivering truly innovative and differentiated technologies.”

Add us as a preferred source on Google

Get the latest Orthopedic Design & Technology news, insights and analysis in your Google Search and AI experiences.

Add Orthopedic Design & Technology as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters

Topics